• 1
    Büller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic diesease. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 401S428S.
  • 2
    Hirsh J, Raschke R. Heparin and low-molecular-weight heparin. The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004; 126: 188S203S.
  • 3
    Arcelus JI, Monreal M, Caprini JA, Suárez C, González-Fajardo JA for the RIETE investigators. The management and outcome of acute venous thrombo-embolism: a prospective registry including 4,011 patients. J Vasc Surg 2003; 38: 91622.
  • 4
    Monreal M, Suárez C, González-Fajardo JA, Barba R, Uresandi F, Valle R, Rondón P for the RIETE Investigators. Management of patients with acute venous thromboembolism: findings from the RIETE Registry. Pathophysiol Haemost Thromb 2003/2004; 33: 3304.
  • 5
    Monreal M, López L, Montero M, González-Fajardo JA, Arcelus JI, Caprini JA for the RIETE Investigators. Venous thromboembolism treatment in the elderly. Findings from the RIETE Registry. Blood 2003; 102: 166a (Abstract).
  • 6
    Monreal M, Kakkar AK, Caprini JA, Barba R, Uresandi F, Valle R, Suárez C for the RIETE Investigators. Is the natural history of venous thromboembolism different in surgical and non-surgical patients? Findings from the RIETE Registry. Blood 2003; 102: 112b (Abstract).
  • 7
    Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989; 87: 14452.
  • 8
    Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis. Am J Med 1996; 100: 26977.
  • 9
    Beyth RJ, Quinn LM, Landefeld S. Prospective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin. Am J Med 1998; 105: 919.
  • 10
    Kuijer PMM, Hutten BA, Prins MH, Büller HR. Prediction of the risk of bleeding during anticoagulant treatment for venous thromboembolism. Arch Intern Med 1999; 159: 45760.
  • 11
    Wicki J, Perrier A, Perneger TV, Bounameaux H, Junod AF. Predicting adverse outcome in patients with acute pulmonary embolism: a risk score. Thromb Haemost 2000; 84: 54852.
  • 12
    Hylek EM, Singer DE. Risk factors for intracraneal hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897902.
  • 13
    Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbion P, Prins MH, Noventa F, Girolami A. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 34848.
  • 14
    Streiff MB. Vena caval filters: a comprehensive review. Blood 2000; 95: 366977.
  • 15
    Schwarz RE, Marrero AM, Conlon KC, Burt M. Inferior vena cava filters in cancer patients: indications and outcome. J Clin Oncol 1996; 14: 6527.
  • 16
    Deitcher SR. Cancer-related deep venous thrombosis: clinical importance, treatment challenges, and management strategies. Semin Thromb Haemost 2003; 29: 24758.
  • 17
    Kelly J, Hnt BJ, Lewis RR, Rudd A. Anticoagulation or inferior vena cava filter placement for patients with primary intracerebral hemorrhage developing venous thromboembolism. Stroke 2003; 34: 29993005.
  • 18
    Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer 1994; 73: 4938.
  • 19
    Altschuler E, Moosa H, Selker RG, Vertosick FT. The risk and efficacy of anticoagulant therapy in the treatment of thromboembolic complications in patients with primary malignant brain tumors. Neurosurgery 1990; 27: 747.